Drug treatment of peptic ulcers is targeted at either counteracting aggressive factors or stimulating the mucosal defense.
Drugs that inhibit or neutralize gastric acid secretion include histamine H2-receptor antagonists, proton pump inhibitors, anticholinergics, prostaglandins and antacids.

The global Peptic Ulcer Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Peptic Ulcer Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Peptic Ulcer Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Peptic Ulcer Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Peptic Ulcer Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Daewoong Pharmaceutical
Takeda Pharmaceutical
Pfizer
Abbott Laboratories
AstraZeneca
Cadila Healthcare
Boehringer Ingelheim
Eisai
Yuhan
GlaxoSmithKline Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
by Product Type
Proton Pump Inhibitors
Potassium-Competitive Acid Blockers
Antacids
H2-Antagonists
Antibiotics
Ulcer Protective Drugs
by Disease Indication
Gastritis
Gastric Ulcer
Duodenal Ulcer
Gastroesophageal Reflux Disease

Segment by Application
Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
E-Commerce